REM-422
ARIA
Remix Therapeutics (merging with Passage Bio) · Phase 1/2 · Recruiting · Enrollment 125
| Arm | Reported safety |
|---|---|
| REM-422 24 mg (RP2D), biomarker positive | n/r |
| REM-422 12 mg or more, biomarker positive | n/r |
| REM-422 24 mg, safety | treatment-related epistaxis (all grade 1 or 2): 60%, cutoff 01.07.2026treatment-related fatigue (all grade 1 or 2): 60%, cutoff 01.07.2026 |
| REM-422 Phase 2 confirmatory cohort | n/r |
A count stays a count. This page does not turn a count into a percent.